Evidence Level:Sensitive: D – Preclinical
Title:
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer
Excerpt:AMG 757 showed potent and specific killing of even those SCLC cell lines with very low DLL3 expression (<1,000 molecules per cell).
DOI:10.1158/1078-0432.CCR-20-2845